We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
-0.04%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$304M
AUM Growth
+$1.15M
(+0.38%)
Cap. Flow
+$57.5M
Cap. Flow
% of AUM
18.92%
Top 10 Holdings %
Top 10 Hldgs %
41.92%
Holding
84
New
27
Increased
13
Reduced
15
Closed
15
Top Buys
| 1 |
Krystal Biotech
KRYS
|
+$7.32M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$4.48M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
+$4.42M |
| 4 |
SLRN
ACELYRIN
SLRN
|
+$4.25M |
| 5 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$3.91M |
Top Sells
| 1 |
AKRO
Akero Therapeutics
AKRO
|
+$11.4M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$8.67M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$7.91M |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
+$7.08M |
| 5 |
Vaxcyte
PCVX
|
+$6.91M |
Sector Composition
| 1 | Healthcare | 67.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $21.9M | 7.2% |
300,000
| – | – |
|
2
MoonLake Immunotherapeutics
MLTX
$1.64B
| $18.8M | 6.19% |
330,000
| – | – |
|
3
CALL
Sarepta Therapeutics
SRPT
$1.82B
| $18.2M | 5.98% |
+150,000
| New | +$17M |
|
|
4
PUT
MoonLake Immunotherapeutics
MLTX
$1.64B
| $14.3M | 4.69% |
+250,000
| New | +$13.8M |
|
|
AKRO
5
CALL
DELISTED
Akero Therapeutics
AKRO
| $12.6M | 4.16% |
+250,000
| New | +$11.6M |
|
|
6
Krystal Biotech
KRYS
$10.5B
| $9.28M | 3.05% |
80,000
+60,000
| +300% | +$7.32M |
|
7
Madrigal Pharmaceuticals
MDGL
$12.8B
| $8.4M | 2.76% |
57,500
+2,500
| +5% | +$471K |
|
8
TG Therapeutics
TGTX
$8.4B
| $8.36M | 2.75% |
1,000,000
+175,000
| +21% | +$2.44M |
|
9
Ascendis Pharma A/S
ASND
$17.1B
| $7.96M | 2.62% |
85,000
-15,000
| -15% | -$1.4M |
|
10
Axsome Therapeutics
AXSM
$11.8B
| $7.69M | 2.53% |
110,000
| – | – |
|
|
ALPN
11
DELISTED
Alpine Immune Sciences Inc
ALPN
| $7.6M | 2.5% |
664,132
+316,700
| +91% | +$3.9M |
|
|
12
Vaxcyte
PCVX
$8.12B
| $7.14M | 2.35% |
140,000
-140,000
| -50% | -$6.91M |
|
|
13
Tarsus Pharmaceuticals
TARS
$2.61B
| $7.11M | 2.34% |
400,000
+250,000
| +167% | +$4.42M |
|
|
APLS
14
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| $7.04M | 2.31% |
+185,000
| New | +$8.13M |
|
15
Protagonist Therapeutics
PTGX
$9.06B
| $6.67M | 2.19% |
400,000
+175,000
| +78% | +$3.4M |
|
16
Cogent Biosciences
COGT
$6.68B
| $6.34M | 2.08% |
650,000
+75,000
| +13% | +$890K |
|
17
CALL
Rocket Pharmaceuticals
RCKT
$376M
| $6.04M | 1.99% |
+295,000
| New | +$5.36M |
|
|
AMAM
18
DELISTED
Ambrx Biopharma Inc
AMAM
| $6.04M | 1.99% |
525,000
+286,775
| +120% | +$3.91M |
|
|
AKRO
19
DELISTED
Akero Therapeutics
AKRO
| $5.82M | 1.91% |
115,000
-245,000
| -68% | -$11.4M |
|
20
Immunovant
IMVT
$8.27B
| $4.99M | 1.64% |
+130,000
| New | +$2.94M |
|
|
21
Sarepta Therapeutics
SRPT
$1.82B
| $4.85M | 1.59% |
40,000
-45,000
| -53% | -$5.09M |
|
22
PUT
Syndax Pharmaceuticals
SNDX
$2.02B
| $4.36M | 1.43% |
+300,000
| New | +$5.67M |
|
23
PMV Pharmaceuticals
PMVP
$71.5M
| $4.33M | 1.43% |
705,881
+424,900
| +151% | +$2.92M |
|
24
CALL
Replimune Group
REPL
$859M
| $4.28M | 1.41% |
+250,000
| New | +$4.91M |
|
25
Viridian Therapeutics
VRDN
$1.99B
| $4.22M | 1.39% |
275,000
+35,000
| +15% | +$668K |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Ghost Tree Capital held 84 positions worth $304M, up 0.38% from $303M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Ghost Tree Capital deployed $57.5M of net new capital in Q3 2023, opening 27 new positions and adding to 13 existing holdings. Its largest new stake was Deciphera Pharmaceuticals, Inc. Common Stock: 325,000 shares worth $4.13M.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 91% a quarter earlier.
On the sell side, the largest reduction was Akero Therapeutics, an estimated $11.4M trimmed.
- Ghost Tree Capital's largest Q3 2023 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 325,000 shares worth $4.13M.
- Ghost Tree Capital added most to Krystal Biotech in Q3 2023, an estimated $7.32M increase.
- Ghost Tree Capital's biggest Q3 2023 reduction was Akero Therapeutics, cutting an estimated $11.4M.
- Ghost Tree Capital fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $8.67M.
- Ghost Tree Capital's ten largest holdings make up 42% of its $304M portfolio in Q3 2023.
- Ghost Tree Capital opened 27 new positions and closed 15 in Q3 2023.
- Ghost Tree Capital's portfolio value rose 0.38% quarter-over-quarter to $304M.
Based on Ghost Tree Capital's 13F filing for Q3 2023, filed 14 Nov 2023.